Norris Medicines Ltd
Incorporated in 1990, Norris Medicines Ltd manufacturers Injections and Medicinal formulations
- Market Cap ₹ 16.6 Cr.
- Current Price ₹ 16.6
- High / Low ₹ 27.7 / 10.7
- Stock P/E
- Book Value ₹ -14.4
- Dividend Yield 0.00 %
- ROCE -8.43 %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -19.1% over past five years.
- Promoter holding is low: 34.0%
- Debtor days have increased from 52.9 to 68.6 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
20.70 | 18.68 | 18.86 | 20.46 | 13.57 | 16.26 | 7.84 | 12.25 | 9.44 | 8.36 | 5.64 | 4.59 | |
21.76 | 16.97 | 18.03 | 20.46 | 15.49 | 16.87 | 10.00 | 14.00 | 9.52 | 7.43 | 5.81 | 4.45 | |
Operating Profit | -1.06 | 1.71 | 0.83 | 0.00 | -1.92 | -0.61 | -2.16 | -1.75 | -0.08 | 0.93 | -0.17 | 0.14 |
OPM % | -5.12% | 9.15% | 4.40% | 0.00% | -14.15% | -3.75% | -27.55% | -14.29% | -0.85% | 11.12% | -3.01% | 3.05% |
0.12 | 0.15 | 0.30 | 0.06 | 0.14 | 0.04 | 0.09 | 0.05 | 0.03 | 0.01 | 0.01 | 0.04 | |
Interest | 0.45 | 0.54 | 0.67 | 0.60 | 0.70 | 0.73 | 0.88 | 1.63 | 1.48 | 1.50 | 0.37 | 0.39 |
Depreciation | 1.17 | 1.31 | 0.60 | 0.65 | 0.71 | 0.71 | 0.73 | 0.67 | 0.66 | 0.63 | 0.57 | 0.53 |
Profit before tax | -2.56 | 0.01 | -0.14 | -1.19 | -3.19 | -2.01 | -3.68 | -4.00 | -2.19 | -1.19 | -1.10 | -0.74 |
Tax % | -42.97% | 10,500.00% | -128.57% | -35.29% | -21.00% | -16.42% | -22.83% | 24.25% | 49.32% | 47.06% | 8.18% | |
-1.45 | -1.04 | 0.04 | -0.77 | -2.51 | -1.68 | -2.84 | -4.96 | -3.26 | -1.75 | -1.19 | -0.84 | |
EPS in Rs | -1.45 | -1.04 | 0.04 | -0.77 | -2.51 | -1.68 | -2.84 | -4.96 | -3.26 | -1.75 | -1.19 | -0.84 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -12% |
5 Years: | -19% |
3 Years: | -23% |
TTM: | -15% |
Compounded Profit Growth | |
---|---|
10 Years: | 2% |
5 Years: | 5% |
3 Years: | 21% |
TTM: | 56% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 44% |
3 Years: | -22% |
1 Year: | 37% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 |
Reserves | -3.58 | -4.63 | -4.60 | -5.36 | -7.88 | -9.55 | -12.39 | -17.36 | -20.62 | -22.37 | -23.56 | -24.28 |
7.52 | 8.16 | 7.51 | 7.57 | 7.71 | 11.24 | 17.92 | 15.52 | 21.08 | 21.40 | 21.52 | 21.58 | |
7.45 | 4.69 | 5.06 | 9.90 | 10.92 | 8.76 | 5.10 | 11.69 | 3.80 | 4.72 | 6.29 | 5.75 | |
Total Liabilities | 21.32 | 18.15 | 17.90 | 22.04 | 20.68 | 20.38 | 20.56 | 19.78 | 14.19 | 13.68 | 14.18 | 12.98 |
8.97 | 8.61 | 8.34 | 9.97 | 9.32 | 8.90 | 8.25 | 7.67 | 7.07 | 6.47 | 5.79 | 5.54 | |
CWIP | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
12.24 | 9.53 | 9.55 | 12.06 | 11.35 | 11.47 | 12.30 | 12.10 | 7.11 | 7.20 | 8.38 | 7.43 | |
Total Assets | 21.32 | 18.15 | 17.90 | 22.04 | 20.68 | 20.38 | 20.56 | 19.78 | 14.19 | 13.68 | 14.18 | 12.98 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
1.44 | -1.43 | 1.35 | -0.96 | 0.80 | -1.92 | -2.88 | 1.11 | -1.01 | 1.20 | 0.17 | |
-1.75 | -0.88 | -0.34 | -2.05 | -0.08 | -0.29 | 0.00 | -0.06 | -0.09 | -0.02 | 0.05 | |
0.02 | 0.10 | -1.32 | 3.16 | -0.66 | 2.18 | 2.86 | -1.09 | 1.10 | -1.18 | -0.20 | |
Net Cash Flow | -0.28 | -2.21 | -0.31 | 0.15 | 0.06 | -0.02 | -0.02 | -0.04 | 0.00 | 0.00 | 0.02 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 91.34 | 73.66 | 53.61 | 84.20 | 66.44 | 67.57 | 128.49 | 53.33 | 42.15 | 48.03 | 68.60 |
Inventory Days | 74.17 | 100.05 | 134.23 | 129.50 | 238.53 | 134.81 | 323.82 | 212.99 | 157.45 | 347.62 | 594.15 |
Days Payable | 151.02 | 111.66 | 99.30 | 125.29 | 252.40 | 139.83 | 233.37 | 218.83 | 86.53 | 149.91 | 244.25 |
Cash Conversion Cycle | 14.50 | 62.06 | 88.54 | 88.41 | 52.56 | 62.55 | 218.94 | 47.49 | 113.06 | 245.73 | 418.51 |
Working Capital Days | 16.22 | 40.84 | 35.22 | -16.06 | -91.18 | -32.55 | -30.73 | -103.69 | 17.40 | 7.86 | -12.94 |
ROCE % | 4.02% | 4.03% | -4.08% | -22.92% | -11.97% | -20.68% | -20.13% | -7.68% | 3.20% | -8.43% |
Documents
Announcements
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
2d - Norris Medicines confirms not classified as Large Corporate under SEBI as of March 31, 2025.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 4 Apr
-
Closure of Trading Window
29 Mar - Closure of trading window until financial results are declared.
-
Integrated Filing (Financial)
14 Feb - Board approved unaudited financial results for Q3 2024.
- Outcome Of Board Meeting Held On 13Th February, 2025 Pursuant To Regulation 33 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015. 13 Feb
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2000
from bse
-
Financial Year 1998
from bse
Business Overview:[1]
Company is in Health Care Industry and does contract manufacturing and Loan License Manufacturing for pharma companies.